2026-04-17T05:33:12Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/117022025-10-24T10:27:24Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Alegre Amor, Adrian
author
ESCALANTE, FERNANDO
author
BERGUA BURGUES, JUAN MIGUEL
author
Martínez-Chamorro, Carmen
author
López, Aurelio
author
Gironella, Mercedes
2025-10-24T10:27:24Z
2025-10-24T10:27:24Z
2024-07-12T08:16:47Z2024-07-12T08:16:47Z2024-07-04
http://hdl.handle.net/11351/11702
Relapse; Multiple myeloma; TreatmentRecaída; Mieloma múltiple; TratamientoRecaiguda; Mieloma múltiple; TractamentRecommendations regarding the best time to start treatment in patients with relapsed/refractory multiple myeloma (RRMM) after biological relapse/progression (BR) are unclear. This observational, prospective, multicenter registry aimed to evaluate the impact on time to progression (TTP) of treatment initiation at BR versus at symptomatic clinical relapse (ClinR) based on the Spanish routine practice in adult patients with RRMM. Patients had two or less previous treatment lines and at least one previous partial response. Baseline characteristics and treatment outcomes were recorded, and survival was analyzed. Of 225 patients, 110 were treated at BR (TxBR group) and 115 at ClinR (TxClinR group) according to the investigators' criteria. The proportion of patients with higher ECOG, previous noncomplete remission (CR), and second relapse were significantly higher in the TxBR group compared to the TxClinR group. TheTxClinR group showed improved outcomes, including TTP, compared to the TxBR group. Progression-free survival increased in the TxClinR group (56.2 months) compared to the TxBR group (32.5 months) (p = 0.0137), and median overall survival also increased (p = 0.0897). Median TTP was significantly longer in patients relapsing from a CR (50.4 months) and in their first relapse (38.7 months) compared to those relapsing from a non-CR response (32.9 months) and in their second relapse (25.2 months). Physicians seemed to start treatment earlier in RRMM patients with poor prognosis features. Previous responses to anti-MM treatment and the number of prior treatment lines were identified as prognosis factors, whereby relapse from CR and first relapse were associated with a longer time to progression.This study was funded by Celgene, a BMS company.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Mieloma múltiple - Tractament
Mieloma múltiple - Recaiguda
Avaluació de resultats (Assistència sanitària)
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Progression-Free Survival
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia libre de progresión
Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion